The startup has developed a patented, non-permanent gene therapy utilizing zinc-finger and CRISPR-based epigenome regulation to target chronic pain without the risk of addiction. This approach addresses the opioid epidemic by providing a specific and long-lasting pain management solution that allows patients to maintain normal sensory function.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic pain management often relies on opioid-based medications, leading to significant risks of addiction and adverse side effects. Current non-opioid pain treatments may lack specificity or long-term efficacy, leaving a gap in effective and safe pain relief options.
Solution
This startup is developing non-permanent gene therapies for chronic pain using zinc-finger and CRISPR-based epigenome regulation. Their approach aims to provide targeted and sustained pain relief without the addictive potential of opioids. By modulating gene expression related to pain pathways, the therapy seeks to restore normal sensory function while minimizing off-target effects. The technology offers a potential alternative for patients seeking long-lasting pain management solutions that address the underlying causes of chronic pain.
Target Audience
The primary target audience includes individuals suffering from chronic pain conditions who are seeking non-addictive and long-lasting pain management solutions.
Features
- Utilizes zinc-finger and CRISPR-based epigenome regulation for targeted gene modulation
- Non-permanent gene therapy approach for reversible and adaptable treatment
- Designed to provide long-lasting pain relief without the risk of addiction
- Aims to restore normal sensory function by targeting specific pain pathways